About Cranebio
Cranebio is a company based in Minato (Japan) founded in 2021. Cranebio has raised $1.67 million across 1 funding round from investors including Axil Capital, Nippon Venture Capital and Akigin Capital Partners. Cranebio operates in a competitive market with competitors including Miltel and MyCode, among others.
- Headquarter Minato, Japan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.67 M (USD)
in 1 rounds
-
Latest Funding Round
$1.67 M (USD), Series A
Oct 04, 2023
-
Investors
Axil Capital
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cranebio
Cranebio has successfully raised a total of $1.67M through 1 strategic funding round. The most recent funding activity was a Series A round of $1.67 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cranebio
Cranebio has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Axil Capital, Nippon Venture Capital and Akigin Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Cranebio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cranebio
Investment portfolio details for Cranebio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cranebio
Detailed financials for Cranebio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cranebio Comparisons
Peer comparison for Cranebio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cranebio
Cranebio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Miltel and MyCode, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Telomere tests for aging detection and cellular senescence are provided.
|
|
| Locked | Locked | Locked |
Provides reliable genetic testing services for personalized health insights.
|
Detailed competitors of Cranebio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cranebio
Complete news archive for Cranebio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cranebio
Cranebio was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Cranebio is headquartered in Minato, Japan. It is registered at Minato, Tokyo, Japan.
Daisuke Yamamoto is the current CEO of Cranebio.
Cranebio is a funded company, having raised a total of $1.67M across 1 funding round to date.
Cranebio was founded in 2021 and is based in Minato, Japan. Operations focus on the biotechnology sector, where self-service genetic test kits for womens health are developed. A wearable testing device and a next-generation rapid kit utilizing DNA origami technology are offered to detect visible light nucleic acids associated with womens hormones and specific diseases. These tools enable at-home analysis without professional intervention.
Cranebio has 3 investors. Key investors include Axil Capital, Nippon Venture Capital, and Akigin Capital Partners.